Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study

被引:8
|
作者
Lopez-Medrano, Francisco [1 ,3 ]
Asin, Maria Asuncion Perez-Jacoiste [1 ]
Fernandez-Ruiz, Mario [1 ]
Carretero, Octavio [1 ]
Lalueza, Antonio [3 ]
Maestro de la Calle, Guillermo [3 ]
Manuel Caro, Jose [4 ]
de la Calle, Cristina [3 ]
Catalan, Mercedes [5 ]
Garcia-Garcia, Rocio [6 ]
Martinez-Lopez, Joaquin [2 ,7 ]
Origuen, Julia [8 ]
Ripoll, Mar [3 ]
San Juan, Rafael [1 ,2 ]
Trujillo, Hernando [9 ]
Sevillano, Angel [9 ]
Gutierrez, Eduardo [9 ]
de Miguel, Borja [3 ]
Aguilar, Fernando [3 ]
Gomez, Carlos [10 ]
Silva, Jose Tiago [1 ]
Garcia-Ruiz De Morales, Daniel [1 ]
Saro-Buendia, Miguel [1 ]
Marrero-Sanchez, Angel [1 ]
Chiara-Graciani, Guillermo [1 ]
Bueno, Hector [11 ]
Paz-Artal, Estela [12 ]
Lumbreras, Carlos [2 ,3 ]
Pablos, Jose L. [2 ,13 ]
Maria Aguado, Jose [1 ,2 ]
机构
[1] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Internal Med, Unit Infect Dis, Madrid, Spain
[2] Univ Complutense Madrid, Sch Med, Dept Med, Madrid, Spain
[3] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Internal Med, Madrid, Spain
[4] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Pharm, Madrid, Spain
[5] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Intens Care Med, Madrid, Spain
[6] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Pneumol, Madrid, Spain
[7] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Hematol, Madrid, Spain
[8] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Emergency Med, Madrid, Spain
[9] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Nephrol, Madrid, Spain
[10] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Oncol, Madrid, Spain
[11] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Cardiol, Madrid, Spain
[12] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Immunol, Madrid, Spain
[13] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Rheumatol, Madrid, Spain
关键词
COVID-19; SARS-CoV-2; Tocilizumab; Corticosteroids; Therapy; Immunomodulation; Outcome; Mortality; RESPIRATORY-DISTRESS-SYNDROME; CYTOKINE STORM; HYPERINFLAMMATION; MULTICENTER; BLOCKADE;
D O I
10.1016/j.ijid.2021.02.099
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The role of combination immunomodulatory therapy with systemic corticosteroids and tocilizumab (TCZ) for aged patients with COVID-19-associated cytokine release syndrome remains unclear. Methods: A retrospective single-center study was conducted on consecutive patients aged >65 years who developed severe COVID-19 between 03 March and 01 May 2020 and were treated with corticosteroids at various doses (methylprednisolone 0.5 mg/kg/12 h to 250 mg/24 h), either alone (CS group) or associated with intravenous tocilizumab (400?600 mg, one to three doses) (CS-TCZ group). The primary outcome was all-cause mortality by day +14, whereas secondary outcomes included mortality by day +28 and clinical improvement (discharge and/or a >2 point decrease on a 6-point ordinal scale) by day +14. Propensity score (PS)-based adjustment and inverse probability of treatment weights (IPTW) were applied. Results: Totals of 181 and 80 patients were included in the CS and CS-TCZ groups, respectively. All-cause 14day mortality was lower in the CS-TCZ group, both in the PS-adjusted (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.17?0.68; P = 0.002) and IPTW-weighted models (odds ratio [OR]: 0.38; 95% CI: 0.21?0.68; P = 0.001). This protective effect was also observed for 28-day mortality (PS-adjusted HR: 0.38; 95% CI: 0.21?0.72; P = 0.003). Clinical improvement by day +14 was higher in the CS-TCZ group with IPTW analysis only (OR: 2.26; 95% CI: 1.49?3.41; P < 0.001). The occurrence of secondary infection was similar between both groups. Conclusions: The combination of corticosteroids and TCZ was associated with better outcomes among patients aged >65 years with severe COVID-19. ? 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [1] Tocilizumab in hospitalized patients with severe COVID-19 pneumonia: A single-center observational study
    Kaya, Huseyin
    Kizilbay, Gozde Oksuzler
    Ilgazli, Ahmet Hamdi
    Ozgur, Emrah Gokay
    [J]. EURASIAN JOURNAL OF PULMONOLOGY, 2024, 26 (01) : 41 - 50
  • [2] A single-center experience of early administration of tocilizumab and corticosteroids in patients with COVID-19 pneumonia
    Milosevic, Ivana
    Barac, Aleksandra
    Jovanovic, Jaroslava
    Vujovic, Ankica
    Stevanovic, Goran
    Todorovic, Nevena
    Milosevic, Branko
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2023, 117 (09) : 668 - 672
  • [3] Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study
    Fernandez-Ruiz, Mario
    Lopez-Medrano, Francisco
    Perez-Jacoiste Asin, Maria Asuncion
    Maestro de la Calle, Guillermo
    Bueno, Hector
    Manuel Caro-Teller, Jose
    Catalan, Mercedes
    de la Calle, Cristina
    Garcia-Garcia, Rocio
    Gomez, Carlos
    Laguna-Goya, Rocio
    Lizasoain, Manuel
    Martinez-Lopez, Joaquin
    Origuen, Julia
    Luis Pablos, Jose
    Ripoll, Mar
    San Juan, Rafael
    Trujillo, Hernando
    Lumbreras, Carlos
    Maria Aguado, Jose
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (02) : 831 - 842
  • [4] Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study
    Kardos, Zsofia
    Szabo, Miklos
    Barath, Zsuzsanna
    Miksi, Agnes
    Olah, Csaba
    Kozma, Adam
    Gergely, Jozsef A.
    Csanky, Eszter
    Szekanecz, Zoltan
    [J]. BIOMEDICINES, 2023, 11 (02)
  • [5] Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID-19 Pneumonia: A Single-Center Retrospective Study
    Radulescu, Amanda
    Istrate, Alexandru
    Muntean, Monica
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 117 : 1 - 7
  • [6] Tocilizumab in patients with severe COVID-19: A single-center observational analysis
    Knorr, John P.
    Colomy, Veronika
    Mauriello, Christine M.
    Ha, Seung
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2813 - 2820
  • [7] Anti-inflammatory therapy in patients with severe COVID-19 pneumonia: A single-center observational study
    Kul, Gulnur
    Degirmencioglu, Gurkan
    [J]. ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2022, 13 (09): : 993 - 998
  • [8] Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
    Bolukcu, Sibel
    KarakuS, Dilara
    Okay, Gulay
    Akkoyunlu, Yasemin
    Sumbul, Bilge
    Durdu, Bulent
    Koc, Meliha Meric
    Aslan, Turan
    [J]. MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2021, 10
  • [9] Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study
    Tomasiewicz, Krzysztof
    Piekarska, Anna
    Stempkowska-Rejek, Justyna
    Serafinska, Sylwia
    Gawkowska, Aleksandra
    Parczewski, Milosz
    Niscigorska-Olsen, Jolanta
    Lapinski, Tadeusz W.
    Zarebska-Michaluk, Dorota
    Kowalska, Justyna D.
    Horban, Andrzej
    Flisiak, Robert
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2021, 19 (01) : 93 - 100
  • [10] Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review
    Roomi, Sohaib
    Ullah, Waqas
    Ahmed, Faizan
    Farooq, Soban
    Sadiq, Usama
    Chohan, Asad
    Jafar, Munnam
    Saddique, Maryum
    Khanal, Shristi
    Watson, Robert
    Boigon, Margot
    [J]. JOURNAL OF MEDICAL INTERNET RESEARCH, 2020, 22 (09)